Waldenström's macroglobulinemia (WM) represents a subset of lymphoplasmacytic lymphomas in which clonally related lymphoplasmacytic cells secrete a monoclonal IgM Ab. 1 Overproduced IgMs can act as cold agglutinins in WM. Upon exposure to cooler temperatures in the periphery, they cause anemia via binding to the erythrocyte Ii-antigen group and classical complement cascade initiation. 2 Treatment of cold-agglutinin-mediated autoimmune hemolytic anemia (AIHA) in WM typically targets the pathogenic B-cell clone [1] [2] [3] [4] or the classical complement cascade. 2, 5, 6 Plasmapheresis rapidly lowers IgM concentrations for immediate disease control. 1 We report for the first time a case of WM with presumed cold-agglutininmediated AIHA refractory to typical therapy, ultimately requiring hematopoietic stem cell transplantation, specifically for anemia control.
1
Overproduced IgMs can act as cold agglutinins in WM. Upon exposure to cooler temperatures in the periphery, they cause anemia via binding to the erythrocyte Ii-antigen group and classical complement cascade initiation. 2 Treatment of cold-agglutinin-mediated autoimmune hemolytic anemia (AIHA) in WM typically targets the pathogenic B-cell clone [1] [2] [3] [4] or the classical complement cascade. 2, 5, 6 Plasmapheresis rapidly lowers IgM concentrations for immediate disease control. 1 We report for the first time a case of WM with presumed cold-agglutininmediated AIHA refractory to typical therapy, ultimately requiring hematopoietic stem cell transplantation, specifically for anemia control.
A 52-year-old female with a history of hypertension, Raynaud's syndrome, and familial WM (low level myd88 c.794T4C (p.Leu265Pro) mutation present; father and grandfather have WM, and brother has WM with related angioedema) presented to the emergency room with worsening livedo reticularis and fatigue.
Since her diagnosis of WM in 2007, the patient's treatment consisted of multiple regimens, including combination therapy with rituximab and bortezomib (2007); rituximab, bortezomib and everolimus with maintenance everolimus (2009-2011) on a clinical trial; rituximab with plasmapheresis for severe hemolysis (2012); weekly rituximab followed by maintenance rituximab every 3 months (2013) for persistent hemolysis; and cyclophosphamide, bortezomib, dexamethasone and rituximab (2014; also for continued severe hemolysis). A bone marrow aspirate performed at the end of her 2014 treatment showed limited (o5%) bone marrow involvement by lymphoplasmacytic cells and a PET-CT showed no evidence of active malignancy. At the time of her acute presentation in mid-2015, she was being treated with bortezomib every other week and rituximab with i.v. Ig every 3 months.
On arrival to the emergency room, the patient appeared to be ill and lethargic. She had mildly icteric sclera and as in previous hemolytic episodes, her entire body (including her palms) was covered with a purple, lacy, reticular rash. She reported decreased urine output and nausea. Physical examination was otherwise normal.
Her laboratory evaluation was notable for a hematocrit of 17%, reticulocyte count of 6.8%, haptoglobin below assay limits and an LDH (lactate dehydrogenase) that was not reportable due to hemolysis (Table 1) . Creatinine was 1.1 mg/dL, total bilirubin was 6.7 mg/dL with a direct bilirubin of 0.3 mg/dL and lactate was 5 mmol/L. Over 4 h, her hematocrit decreased to 6% and her creatinine rose to 1.6 mg/dL. Given concern for acute hemolytic anemia due to cold agglutinins, she was warmed and received seven units of warmed, packed RBC, broad-spectrum antibiotics, high-dose steroids and underwent emergent plasmapheresis. She also underwent hemodialysis for presumed pigment nephropathy. Following initial stabilization, she was treated with the terminal complement inhibitor, eculizumab.
Further laboratory investigation revealed a positive polyspecific direct antiglobulin test (DAT) and a positive DAT against complement, with a negative DAT against IgG. The patient's M-spike was 0.32 g/dL and the serum kappa-to-lambda free light-chain ratio was 220.70. Her IgM level was 310 mg/dL (her baseline range was 240-480 mg/dL), IgG level was 462 mg/dL, IgA level was 28 mg/dL, C3 level was within normal limits and C4 level was below assay limits. Cold-agglutinin screen was negative and a screen for antibodies against RBC was negative, as noted during prior hemolysis episodes. A Donath-Landsteiner test, flow cytometry for paroxysmal nocturnal hemoglobinuria (CD55, CD59 and CD14), and repeated cryoglobulin screens were all negative. There was no evidence of iron deficiency.
On hospital day (HD) 18, the patient was found to be unresponsive with diffuse livedo reticularis and a hematocrit of 5.5%, down from 19.7% the previous day. Hemolysis labs were strikingly positive (Table 1) , including a plasma hemoglobin of 135 mg%. She received warmed packed RBC and high-dose steroids, and daily plasmapheresis was resumed. Following stabilization, she was initiated on a regimen of daily plasmapheresis with eculizumab and hemodialysis as needed. This was eventually spaced to twice weekly plasmapheresis. The patient's hematocrit stabilized. Workup revealed no new causes for the sudden drop in hematocrit. Throughout this time, no infectious sources were identified. Blood cultures, computed tomography of the chest/abdomen/pelvis, cholescintigraphy, and screens for adenovirus, parvovirus, influenza, RSV, mycoplasma, CMV, Epstein Barr Virus, HIV, HTLV, syphilis, Ehrlichia, Babesia and Hepatitis B/C were all negative. Ibrutinib was initiated on HD 29 given continued breakthrough of disease and was accompanied by twice-weekly plasmapheresis with immediate post-pheresis eculizumab dosing. Despite initial improved control on ibrutinib, the patient had several recurrences of acute albeit milder hemolysis.
Given recurrent episodes of acute hemolysis despite multiple regimens to control her underlying WM and the use of complement inhibitors, the decision was made to proceed with allogeneic hematopoietic stem cell transplantation. Until a match was found, she continued on daily plasmapheresis. A 21-year-old matched unrelated donor was identified, and the patient underwent conditioning with melphalan and fludarabine on HD 65. She received the allo-graft on HD 71 and subsequently initiated sirolimus, tacrolimus and methotrexate for GvHD prophylaxis.
After transplantation, she demonstrated no further evidence of hemolysis and plasmapheresis was discontinued. She was discharged home on HD 91 and remains without evidence of recurrent hemolysis or transplant complications 48 months after transplantation. No complement gene mutations were identified upon pretransplant whole-exome sequencing.
Fifty-one percent of patients experience autoimmune phenomena in conjunction with their WM, and cold agglutinins are present in 5-10% of patients with WM. AIHA is found in 10-20% of those with WM. 7 However, in contrast to the severe, refractory hemolysis seen in this patient, the hemolysis observed in association with chronic lymphoproliferative disorders is typically mild and chronic. 8 The case presented here is unique owing to the lack of association between the pace of hemolysis and burden of WM, the lack of an identifiable autoantibody, and the patient's lack of response to multiple lines of therapy used in WM and AIHA. Despite the patient experiencing several episodes of profound hemolysis, her burden of disease as assessed by IgM level was never significantly above her baseline of 240-480 mg/dL, with values o 1000 mg/dL generally considered a low burden of disease. 1 The pattern of her hemolysis was typical for cold-agglutinin disease (positive anti-complement DAT, a negative DAT against IgG, and consistent association with livedo reticularis), however, no causative autoantibody could be identified and no clear causative association with cold exposure has been established. Typically, autoantibodies in cold-agglutinin disease show specificity against the Ii blood group system with~90% of autoantibodies directed against I Ag and the remaining 10% against i. 8 However, the IgM autoantibodies responsible for cold-agglutinin disease are often times difficult to detect due to their low avidity, and it has been demonstrated that undetected anti-RBC IgM causes complement activation among patients with erythrocyte complement deposition, even in the absence of IgM autoantibody detection via traditional methods. 9 This patient was notably refractory to all standard therapies for WM and cold-agglutinin disease. Standard of care for WM consists of rituximab or rituximab in combination with alkylators, proteasome inhibitors, nucleoside inhibitors or ibrutinib. 1 Regimens consisting of a combination of bortezomib, dexamethasone and rituximab 10 and carfilzomib, rituximab and dexamethasone 11 are used in patients with non-emergent paraprotein-related morbidity. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is an additional monotherapy option with proven efficacy in previously treated patients, and specifically in those with MYD88 L265P mutations. 12 Plasmapheresis is initiated for patients in need of immediate paraprotein control. 1 Stem cell transplants are reserved for salvage therapy in WM, with an overall response rate of 76%. 1, 13 They have not previously been utilized for the acute treatment of coldagglutinin disease in the setting of WM.
Typical treatment for cold-agglutinin disease includes rituximab. Plasmapheresis can provide temporary improvement in cases of severe hemolysis, but must be combined with concomitant immunosuppressive therapy. 8 More recently, eculizumab, a monoclonal Ab that targets the complement protein C5 has shown promise for treating disorders of intravascular hemolysis. 5, 6, 14, 15 In the setting of cold-agglutinin disease, it has resulted in reduced hemolysis, reduced transfusion requirements and improved quality of life even in the absence of a reduction in cold-agglutinin titers. 5, 14 The patient described experienced inadequate disease control from all of the above methods. Despite not having evidence of a significant imaging or laboratory burden of WM, she has now had a sustained response to allogeneic hematopoietic stem cell transplantation with sirolimus and tacrolimus therapy. We thus report for the first time the use of allogeneic stem cell transplantation to treat severe, refractory presumed cold-agglutinin disease secondary to a lymphoproliferative disorder.
